Prevalence of Sexually Transmitted Infections (STIs) Into Prison in Reunion (PRECARIST)

• ClinicalTrials.gov Identifier: NCT04611919
• Recruitment Status: Completed
• First Posted: November 2, 2020
• Last Update Posted: November 2, 2020
• Sponsor: Centre Hospitalier Universitaire de la Réunion
• Information provided by (Responsible Party): Centre Hospitalier Universitaire de la Réunion

Study Description

Brief Summary:

Since the beginning of the 2000s, there has been a steady increase in the incidence of STIs in France. In Reunion, the few figures available seem to show the same phenomenon, especially for syphilis. The unfavorable socio-economic context, which is characterized by high levels of precariousness, significant population exchanges (immigration, travel) with neighboring countries, behaviors around sexuality or screening for STIs different from those observed in mainland France are all factors testify to the singularity of the Reunion island in relation to the metropolitan France with regard to the risk factors of STIs.

STI management has become a priority in public health; in particular, the 2010-2014 HIV and STI control plan emphasized the need for their surveillance and screening. These are often asymptomatic infections that can cause serious complications if they are not treated (infertility, ectopic pregnancies, maternal-fetal infections, ...). Screening them in at-risk populations is therefore essential to reduce their prevalence.

The prison population is a vulnerable population, possibly exposed during the incarceration but also upstream of it (generally low levels of education, over-represented disadvantaged social categories, low access and use of care, high prevalence of risky behaviors). ). Some prevalence studies of STIs in these populations have been carried out in metropolitan France, indicating a prevalence higher than that observed in the general population. There is little data on the subject for the prison population in Réunion; Given the local specificities, it seems necessary to improve the epidemiological knowledge of STIs in this prison population in Réunion, in order to be able to adapt the prevention and care measures, the conditions of detention presenting potentially aggravating situations (promiscuity, confinement). , hygienic conditions, ...).

Condition or disease
Sexually Transmitted Diseases

Study Design

• Study Type: Observational
• Actual Enrollment: 700 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Prevalence of Sexually Transmitted Infections (STIs) at Entry Into Prison in Reunion
• Actual Study Start Date: June 19, 2018
• Actual Primary Completion Date: September 18, 2019
• Actual Study Completion Date: September 30, 2019

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. Prevalence of Sexually Transmitted Infection with Chlamydia trachomatis, Neisseria gonorrheae and Mycoplasma genitalium [ Time Frame: Day 1 ]
   Proportion of people with a positive triplex Polymerase Chain Reaction result of detection of Chlamydia trachomatis, Neisseria gonorrheae and/or Mycoplasma genitalium on samples.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes
• Sampling Method: Non-Probability Sample

Study Population

Screening will be offered to all adults entering prison at Domenjod prison (Reunion Island) between 01/02/2018 and 30/04/2019.

Criteria

Inclusion Criteria:

• imprisoned at Domenjod prison between 01/02/2018 and on 04/30/2019
• able to answer a questionnaire,
• domiciled in Réunion at the time of incarceration,
• incarceration medical examination carried out within 7 days incarceration,

Exclusion Criteria:

• incarcerated by transfer from another penal institution
• having had antibiotic therapy in the 3 months before the inclusion consultation.

Contacts and Locations

Locations

Réunion

Centre Hospitalier Universitaire de La Réunion

Saint-Denis, Réunion, 97400

Sponsors and Collaborators

Centre Hospitalier Universitaire de la Réunion

Investigators

• Principal Investigator: Marie-Pierre MOITON, MD; CHU de La Réunion

More Information

• Responsible Party: Centre Hospitalier Universitaire de la Réunion
• ClinicalTrials.gov Identifier: NCT04611919
• Other Study ID Numbers: 2016/CHU/11
• First Posted: November 2, 2020
• Last Update Posted: November 2, 2020
• Last Verified: October 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Sexually Transmitted Diseases; Infections; Communicable Diseases; Disease Attributes; Pathologic Processes